A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL).
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: James Isaacs, Lucy Boyce Kennedy, Anthony P. Tufaro, Mark D. DeLacure, Anthony Visioni, Eren Berber, Daniel Raymond, Paolo Fabrizio Caimi, John C. Molina, Yee Peng Phoon, Joshua Arbesman, Jennifer S. Ko, Jan Joseph Melenhorst, Joseph J. Skitzki, Craig Steven Sauter, Brian Gastman, Thach-Giao Truong
Institutions: Cleveland Clinic, Iovance Biotherapeutics (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Iovance Biotherapeutics
OpenAlex ID: W4410804829